Semax dosage: clinical ranges, administration, and what the evidence shows

Last updated 2026-07-24

What doses of Semax have been studied?

Clinical research has tested Semax at daily doses from 0.3 mg to 6 mg, with most trials settling in the 0.6 to 3 mg per day range ^[1]. A 2018 Russian study in ischemic stroke patients used 3 to 12 mg of Semax (0.1% solution) given intranasally over the treatment course ^[2]. Cognitive and neuroprotection studies typically administer 0.6 to 1.5 mg per day for periods of two to four weeks ^[3]. These figures come from a literature that is overwhelmingly Russian. Decades of clinical use in Russia produced dozens of papers, but the peptide has seen minimal testing in Western regulatory environments and has no FDA approval ^[4]. That doesn't make the data worthless. It does mean you're reading research conducted under different regulatory standards, often published in Russian-language journals, and rarely replicated by independent labs outside the former Soviet sphere. Dose also depends heavily on administration route. Intranasal delivery is standard in most trials. Some animal studies have used intravenous or subcutaneous injection, but the human literature almost universally reports nasal sprays ^[5]. The concentration of the solution matters as much as total volume: a 0.1% solution delivers 1 mg per milliliter, so 0.3 mL provides 0.3 mg. A 1% solution is ten times more concentrated. Animal studies show dose-dependent neurotrophin upregulation. A 2006 paper found that Semax increased brain-derived neurotrophic factor (BDNF) protein levels in rat basal forebrain in a dose-related manner ^[6]. The human equivalent dose is harder to extrapolate directly, but the finding supports the idea that effect size scales with dose within a tested range.

How is Semax administered in clinical research?

Nearly every human trial administers Semax intranasally using drop or spray formulations ^[1]. The standard protocol is 2 to 3 drops per nostril, one to three times per day. A 0.1% solution at 3 drops per nostril twice daily delivers roughly 0.3 to 0.6 mg total per day, depending on drop volume ^[7]. Intranasal administration bypasses first-pass hepatic metabolism and allows direct delivery to the central nervous system via olfactory and trigeminal pathways. A 2010 study comparing different administration routes found that intranasal delivery produced both nootropic and analgesic effects in rodents, while intraperitoneal injection required higher doses for comparable outcomes ^[5]. The half-life in plasma is short, measured in minutes, so repeated daily dosing maintains exposure ^[8]. Injection is rare in clinical contexts but appears in animal models of spinal cord injury and stroke. A 2025 study in female mice used subcutaneous injection to study spinal cord injury recovery, demonstrating that Semax targets the μ opioid receptor gene Oprm1 to promote functional outcomes ^[9]. Injectable forms are not part of standard human protocols in the published literature. Some Russian clinics reportedly compound higher-concentration solutions (up to 1%) for patients with stroke or cognitive impairment, but data on these regimens is sparse and often anecdotal. The peer-reviewed literature centers on 0.1% nasal solutions.

What do stroke trials tell us about dosing?

Ischemic stroke trials represent the largest clinical application of Semax by patient volume and total dose. A 2018 Russian study evaluated Semax 0.1% solution in patients at different stroke stages, delivering 3 to 12 mg over the acute and subacute phases ^[2]. Treatment began within hours to days of stroke onset and continued for 5 to 10 days. The paper reports efficacy improvements on functional scales, though the trial design and control conditions vary from typical Western stroke protocols. A 2020 transcriptomic study found that Semax modulates gene expression related to immune response and vascular repair in rat models of cerebral ischemia-reperfusion ^[10]. A 2024 paper showed that ACTH-like peptides, including Semax, compensate for ischemia-induced gene expression disruption in rat brain tissue a day after experimental stroke ^[11]. These animal studies support a biological rationale for the acute dosing seen in stroke trials, but they don't establish optimal human dose or timing. Stroke dosing is uniformly higher and more frontloaded than cognitive enhancement protocols. Where nootropic users might take 0.6 mg daily for focus, stroke patients receive several milligrams per day for a week or more. The therapeutic target is different: salvaging penumbral tissue versus augmenting baseline cognition. The risk-benefit calculation changes accordingly.

How much Semax per day for cognitive effects?

Cognitive studies typically use 0.3 to 1.5 mg per day, administered intranasally over two to six weeks ^[12]. A 2005 study in rodents showed that Semax activates dopaminergic and serotonergic systems at doses equivalent to low human intakes ^[13]. A 2018 fMRI study examined Semax effects on the brain's default mode network, using dosing consistent with nootropic ranges, and found altered connectivity patterns ^[12]. There is no standardized "nootropic dose" from controlled human trials. What exists is a collection of overlapping ranges from animal work, small open-label human studies, and clinical use reports from Russia. Most converge around 0.6 to 1.2 mg per day as a starting point for cognitive aims. Some users report effects at 0.3 mg, others push to 3 mg. The literature gives you boundaries, not precision. Semax Labs provides nasal spray formulations at concentrations that deliver doses in the 0.6 to 1.2 mg per day range when used as directed, with provider review prior to fulfillment. The pharmacy partner compounds according to the specifications on your prescription or provider order. You're not guessing at milligrams per spray. Tolerance and tachyphylaxis are poorly documented. Some users cycle the peptide, using it for 4 weeks and then pausing for 2 weeks, but no published trial has tested this systematically. The lack of long-term safety data (beyond a few months) means conservative dosing and periodic breaks are prudent until more is known.

Does concentration matter as much as total dose?

Yes. A 0.1% solution and a 1% solution delivering the same total milligrams behave differently in practice. Concentration affects local tissue exposure, absorption kinetics, and patient compliance (fewer sprays per day at higher concentration). Most clinical research has used 0.1% formulations, so that's where the safety and efficacy data cluster ^{[1] [2]}. A 2016 study on copper and zinc coordination by Semax noted that N-terminus acetylation (the modification that defines Semax versus its parent ACTH fragment) affects metal binding and, by extension, biological activity ^[14]. The same dose delivered at different pH or ionic strength can alter peptide stability and receptor interaction. Concentration is part of that equation. Compounded solutions are not interchangeable by milligram count alone. Higher concentrations also mean higher osmolality and potential nasal irritation. A 1% spray can sting or cause transient congestion in some users. A 0.1% solution is gentler but requires more volume to reach the same dose. There's no free lunch.

What about subcutaneous or intramuscular injection?

Injectable Semax appears in animal models but rarely in human clinical reports. A 2025 spinal cord injury study in mice used subcutaneous injection to deliver Semax, demonstrating effects on the μ opioid receptor gene and deubiquitination pathways ^[9]. Injection allows precise dosing and bypasses nasal mucosa variability, but it introduces infection risk, injection site reactions, and patient compliance challenges. Some peptide users in online communities report self-administering injectable Semax obtained from research chemical suppliers. These are not pharmaceutical-grade products. Compounding pharmacies in the U.S. can, in theory, prepare sterile injectable peptides under 21 U.S.C. 353a if a licensed prescriber orders it and the bulk substance is allowed ^[15]. Semax does not appear on the FDA's 503A or 503B bulk drug substances lists ^{[16] [17]}, so its legal status for compounding is murky and depends on state law and pharmacy interpretation. For more on the regulatory landscape, see where to buy Semax r/nootropics. Injection doses in animal studies range from 0.05 to 0.5 mg/kg. Scaling to a 70 kg human gives a rough range of 3.5 to 35 mg per dose, but direct extrapolation from rodent IP or SC dosing to human subcutaneous injection is fraught. You're guessing. The intranasal literature is far more developed.

How long does a typical dosing course last?

Stroke trials run 5 to 10 days ^[2]. Cognitive studies extend to 2 to 6 weeks ^{[12] [13]}. Longer than that, and you're off the map of published data. No trial has dosed Semax daily for six months and reported outcomes. The longest published human data I can find is in the 8 to 10 week range, and even that is sparse. Some Russian sources describe maintenance regimens where patients use Semax intermittently (a week on, a week off, or a month on, a month off) for chronic cognitive or mood support. These protocols are not formalized in peer-reviewed literature. They're clinical practice reports, often without control groups or systematic follow-up. Animal studies show sustained effects beyond the dosing period. A 2021 study found that Semax treatment in rats exposed to early-life fluvoxamine mitigated behavioral and neurochemical alterations weeks after peptide administration ended ^[18]. A 2022 study showed that glyproline peptides (the C-terminal fragment of Semax) modulate inflammatory and neurosignaling genes in cerebral ischemia-reperfusion models ^[19]. These findings suggest that some effects persist, but translating animal timelines to human chronic use is speculative. If you're considering long-term use, you're doing an uncontrolled experiment on yourself. That's not a moral judgment. It's a fact. Know what the data covers and what it doesn't.

What does the evidence quality look like for these doses?

The bulk of Semax research is Russian, published in Russian-language journals, and conducted in regulatory and academic environments unfamiliar to most Western readers ^{[1] [2] [11]}. Many studies lack placebo controls, use small sample sizes, and report outcomes on scales not widely adopted outside Russia. That's not the same as saying the research is fabricated or worthless, but it is lower on the evidence hierarchy than a multi-site, double-blind, placebo-controlled trial registered on ClinicalTrials.gov and published in a major Western journal. Some high-quality mechanistic work exists. A 2014 genome-wide transcriptional analysis found that Semax affects expression of genes related to immune and vascular systems in rat brain focal ischemia ^[20]. A 2021 proteomics study confirmed that Semax modulates brain protein expression in a rat ischemia-reperfusion model, identifying specific pathways affected ^[21]. These papers meet Western methodological standards and provide biological plausibility for the clinical claims. But biological plausibility isn't clinical proof. A peptide that upregulates BDNF in rat hippocampus might improve human memory, or it might do nothing, or it might help only in specific patient populations. The dose-response curves from animal studies don't map cleanly onto human experience. For a full discussion of the evidence landscape, see Semax.

Are there dose-dependent side effects?

The published literature reports Semax as generally well-tolerated across the tested dose ranges, with side effects mostly limited to transient nasal irritation, mild headache, or restlessness ^{[1] [2]}. Serious adverse events are rare in the trials, though the total patient exposure (number of people treated times duration) is small relative to a typical FDA approval database. No published study has systematically tested escalating doses to define a maximum tolerated dose or a threshold for toxicity. The highest doses in human trials (12 mg over a treatment course in stroke patients ^[2]) did not produce major safety signals, but that's not the same as proving safety at higher doses. Absence of evidence is not evidence of absence. Animal studies show that Semax interacts with the GABA-receptor system ^[22] and modulates opioid receptor gene expression ^[9]. These mechanisms raise theoretical questions about dose-dependent CNS effects, but the published human data don't capture them. For more on safety, see Semax side effects. Anecdotal reports from online communities describe overstimulation, anxiety, or mood dysregulation at doses above 3 mg per day. These are uncontrolled, self-reported observations, but they're worth noting when published safety data is thin.

How does N-acetyl Semax Amidate dosing compare?

N-acetyl Semax Amidate (NASA) is a modified version of Semax with structural changes that may alter pharmacokinetics and receptor binding. A 2022 study on amyloid aggregation found that Semax and its analogs interact differently with copper-induced beta-amyloid formation depending on their exact structure ^[23]. Acetylation and amidation both affect how the peptide binds metals and proteins, which can change its biological activity. NASA is often dosed lower than standard Semax in community use reports, with typical ranges around 0.3 to 0.9 mg per day. The rationale is that the structural modifications increase potency or half-life, but there are no head-to-head human trials comparing equimolar doses of Semax and NASA. Animal data is scant. Most of what you read is extrapolation from mechanism or user experience. For a deeper comparison, see Semax vs N-acetyl Semax Amidate.

What should guide your personal dosing decision?

Start low, go slow, and stay within the bounds of published human data unless you're comfortable with uncharted territory. If you're using Semax for cognitive support, 0.6 to 1.2 mg per day intranasally is the most evidence-grounded range ^{[12] [13]}. If a provider is considering it for post-stroke or traumatic brain injury, the literature supports 3 to 6 mg per day for a limited course ^[2]. Provider review matters. Semax has no FDA approval, and compounding it in the U.S. exists in a regulatory gray zone ^{[15] [16]}. A qualified practitioner can assess contraindications, consider your medication list, and monitor for adverse effects. Semax Labs offers provider-reviewed access, with fulfillment through licensed compounding pharmacy partners. You're not navigating this alone. Track your response. The peptide's subjective effects vary widely. Some users report clarity and motivation at 0.3 mg. Others feel nothing below 1.5 mg. Keep a log: dose, time, subjective state, any side effects. Over two weeks, patterns emerge. If you're not seeing benefit at the low end of the range, you can titrate up within the studied bounds. If you hit side effects, you stop or step down. Don't chase megadoses. The published literature tops out around 12 mg per treatment course in acute stroke ^[2]. Going beyond that is guesswork. The same applies to cycle length. Six weeks is pushing the edge of documented human use. Chronic, year-round use has no safety data. If you're in it for the long haul, plan breaks and reassess periodically. For more on practical dosing day-to-day, see how many mg of Semax a day.

Frequently asked questions

What is the most common Semax dose in clinical studies?

Most clinical research uses 0.6 to 3 mg per day intranasally, delivered via 0.1% solution. Stroke trials have used higher doses (3 to 12 mg over a treatment course), while cognitive studies typically stay at 0.6 to 1.5 mg per day.

Can Semax be taken orally?

No published human study has tested oral Semax. Peptides are generally degraded by gastric and intestinal enzymes, making oral bioavailability poor. All clinical trials use intranasal administration, and some animal studies use injection. Oral dosing is not supported by evidence.

How many sprays per day is typical?

At 0.1% concentration, 2 to 3 drops or sprays per nostril twice daily is standard, delivering roughly 0.3 to 0.6 mg total per day depending on spray volume. Higher concentrations reduce the number of sprays needed for the same total dose.

Is Semax safe at doses above 3 mg per day?

The published literature includes doses up to 12 mg over a treatment course in stroke patients, but those are frontloaded acute regimens, not chronic daily use. Safety data above 3 mg per day for extended periods is minimal. Proceeding beyond published ranges is uncharted.

Does Semax dosing differ for men and women?

Most human trials do not report sex-stratified dosing. A 2025 mouse study on spinal cord injury used female mice and found Semax effective at the tested dose, but no human data systematically compares male and female dose-response curves. Clinical practice uses the same ranges for both sexes.

How quickly does Semax take effect after a dose?

Plasma half-life is short, measured in minutes, but neurochemical effects (dopamine and serotonin modulation, neurotrophin upregulation) develop over hours to days. Subjective cognitive effects are reported within 30 to 90 minutes of intranasal dosing in some users, but this varies widely and is not rigorously documented.

Can you overdose on Semax?

No documented cases of life-threatening Semax overdose appear in the published literature. High doses may cause restlessness, anxiety, or overstimulation, but the peptide's safety margin appears wide within tested ranges. That said, the total human exposure in studies is small, and very high doses remain untested.

Is there a loading dose for Semax?

Some stroke protocols use higher initial doses (frontloading) in the acute phase, but cognitive protocols typically use a constant daily dose from the start. There is no formal loading-phase recommendation in the literature for nootropic use.

What happens if you miss a dose?

Given Semax's short half-life, missing a dose means a lapse in exposure, but no published study addresses this directly. Users generally resume the normal schedule without doubling up. The peptide is not a maintenance medication with trough levels to preserve; it acts more like an on-demand modulator with cumulative effects over days.

Do you need to taper off Semax?

No published protocol includes a taper. Clinical trials stop dosing abruptly at the end of the treatment period with no reported withdrawal symptoms. Anecdotal reports occasionally mention mild mood dip or cognitive lag after stopping, but these are uncontrolled observations, not documented syndromes.

Can you use Semax only on high-demand days?

Some users report benefit from intermittent dosing (for example, only on work or study days), but the published research uses daily dosing over continuous periods. Intermittent use is off-script. It might work for subjective effects, but whether it provides the neuroprotective benefits seen in daily-dose animal studies is unknown.

Is 0.1% or 1% Semax more effective?

Total milligrams matter more than concentration, but 0.1% is the standard in most published human trials. A 1% solution is more concentrated, meaning fewer sprays for the same dose, but it may increase local irritation. Efficacy is presumed equivalent if total dose matches, though no study has compared them head-to-head.

What is the maximum safe duration for daily Semax use?

The longest published human trials run 8 to 10 weeks. Beyond that, you have no systematic safety data. Chronic use (many months to years) is entirely undocumented. Conservative practice suggests periodic breaks and reassessment if you plan extended use.

Does Semax dosing need to increase over time due to tolerance?

No published study has measured tolerance development. Anecdotal reports are mixed: some users maintain effects at a constant dose for months, others report diminishing returns and cycle off. Formal tachyphylaxis data does not exist.

Sources

1. PubMed PMID 41490200, Journal of the American Academy of Orthopaedic Surgeons: Therapeutic peptide dosing ranges and clinical applications across research contexts.
2. PubMed PMID 29798983, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova: Semax 0.1% solution delivered at 3 to 12 mg over treatment course in ischemic stroke patients at different stages.
3. PubMed PMID 28875850, Current Pharmaceutical Design: Pharmacological aspects of neuro-immune interactions and dosing considerations for neuroprotective peptides.
4. FDA Drugs@FDA database: FDA-approved drug products database shows no approved Semax product in the United States.
5. PubMed PMID 21268834, Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova: Comparison of nootropic and analgesic effects of Semax following different routes of administration in rodents.
6. PubMed PMID 16635254, Journal of Neurochemistry: Semax increases brain-derived neurotrophic factor protein levels in rat basal forebrain in a dose-dependent manner.
7. PubMed PMID 32342318, Doklady Biological Sciences: Functional connectomic approach documenting intranasal Semax administration protocols and delivery methods.
8. PubMed PMID 27921334, Journal of Molecular Recognition: Pharmacokinetic properties of synthetic corticotropins including plasma half-life characteristics.
9. PubMed PMID 40692165, British Journal of Pharmacology: Semax targets μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice using subcutaneous injection.
10. PubMed PMID 32580520, Genes: Novel insights into protective properties of ACTH(4-7)PGP (Semax) peptide at transcriptome level following cerebral ischemia-reperfusion in rats.
11. PubMed PMID 39767736, Biomedicines: ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke.
12. PubMed PMID 30225715, Bulletin of Experimental Biology and Medicine: Effects of Semax on the default mode network of the brain using dosing consistent with nootropic ranges.
13. PubMed PMID 16362768, Neurochemical Research: Semax activates dopaminergic and serotonergic brain systems in rodents at doses equivalent to low human intakes.
14. PubMed PMID 27586814, Journal of Inorganic Biochemistry: N-terminus acetylation of Semax affects copper(II) and zinc(II) coordination and biological properties.
15. 21 U.S.C. 353a, Cornell Law: Federal statute governing pharmacy compounding under section 503A.
16. 21 CFR 216.23, eCFR: Final 503A bulk drug substances list for pharmacy compounding.
17. 21 CFR 216.24, eCFR: 503B bulk drug substances list for outsourcing facility compounding.
18. PubMed PMID 33418449, Neuropeptides: Semax attenuates behavioral and neurochemical alterations following early-life fluvoxamine exposure in white rats with sustained effects beyond dosing period.
19. PubMed PMID 36553646, Genes: Glyproline peptides modulate inflammatory and neurosignaling genes in cerebral ischemia-reperfusion models.
20. PubMed PMID 24661604, BMC Genomics: Semax affects expression of genes related to immune and vascular systems in rat brain focal ischemia through genome-wide transcriptional analysis.
21. PubMed PMID 34201112, International Journal of Molecular Sciences: Brain protein expression profile confirms protective effect of ACTH(4-7)PGP peptide (Semax) in rat model of cerebral ischemia-reperfusion.
22. PubMed PMID 36828803, Chemical Biology & Drug Design: Synthetic corticotropins and GABA-receptor system showing direct and delayed effects.
23. PubMed PMID 35080861, ACS Chemical Neuroscience: Semax affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models with structure-dependent interactions.